Frequencies of Single-Nucleotide Polymorphisms and Haplotypes of the SLCO1B1 Gene in Selected Populations of the Western Balkans

1. Liu J, Long J, Zhang S, Fang X, Luo Y. Polymorphic variants of SLCO1B1 in neonatal hyperbilirubinemia in China. Ital J Pediatr. 2013; 39(49): 1-5.10.1186/1824-7288-39-49375062224090270Search in Google Scholar

2. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Piсan MA, Garcia-Miguel P, Navajas A, et al. Polymor- phisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011; 57(4): 612-619.10.1002/pbc.2307421387541Search in Google Scholar

3. Niemi M, Kivistц KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. Fexofenadine pharmacokin- etics is associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol. 2005; 59(5): 602-604.10.1111/j.1365-2125.2005.02354.x188484415842561Search in Google Scholar

4. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005; 77(6): 468-478.10.1016/j.clpt.2005.01.01815961978Search in Google Scholar

5. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the phar-macokinetics of atorvastatin and rosuvastatin. Clin Phar-macol Ther. 2007; 82(7): 726-733.10.1038/sj.clpt.610022017473846Search in Google Scholar

6. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, et al. Drug and bile acid transporters in rosuva statin hepatic uptake: Function, expression and pharmaco genetics. Gastroenterology. 2006; 130(6): 1793-1806.10.1053/j.gastro.2006.02.03416697742Search in Google Scholar

7. Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, Shiroyanagi Y, et al. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1- receptor. Drug Metab Dispos. 2007; 35(12): 2166-2176.10.1124/dmd.107.01745917823233Search in Google Scholar

8. Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, et al. Vectorial transport of enalapril by Oatp 1a1/Mrp2 and OATP1B1 and OATP1B3/ MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006; 318(1): 395-402.10.1124/jpet.106.10339016627748Search in Google Scholar

9. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther. 2006; 80(6): 565-581.10.1016/j.clpt.2006.09.00317178259Search in Google Scholar

10. Vavricka SR, Van Mootfort J, Ha HR, Meier PJ, Fattinger K. Interactions of ryfamycin Sv and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002; 36(1): 164-172.10.1053/jhep.2002.3413312085361Search in Google Scholar

11. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics. 2008; 9(1): 19-33.10.2217/14622416.9.1.1918154446Search in Google Scholar

12. Tirona RG, Leake BF, Merino G, Kim RB. Poly-morphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European- and African- Americans. J Biol Chem. 2001; 276(38): 35669-35675.10.1074/jbc.M10379220011477075Search in Google Scholar

13. Pasanen MK, Backman JT, Neuvonen PJ, Niemi M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol. 2006; 62(6): 409-415.10.1007/s00228-006-0123-116758257Search in Google Scholar

14. Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan and temocapril. Clin Pharmacol Ther. 2006; 79(5): 427-439.10.1016/j.clpt.2006.01.01116678545Search in Google Scholar

15. Oswald S, Konig J, Lutjohann D, Giessmann T, Kroemer HK, Rimmbach C, et al. Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet Genomics. 2008; 18(7): 559-568.10.1097/FPC.0b013e3282fe9a2c18551036Search in Google Scholar

16. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymoprhism and sex affect the pharmacokinetics of pra-vastatin but not fluvastatin. Clin Pharmacol Ther. 2006; 80(4): 356-366.10.1016/j.clpt.2006.06.01017015053Search in Google Scholar

17. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, et al. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan - Pharmacoknetics and clinical outcome of patients with advanced non-small lung cancer. Lung Cancer. 2008; 59(1): 69-75.10.1016/j.lungcan.2007.07.01917766002Search in Google Scholar

18. SEARCH Collaborative group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO 1B1 variants and statin-induced myopathy - A genomewide study. N Engl J Med. 2008; 359(8): 789-799.10.1056/NEJMoa080193618650507Search in Google Scholar

19. Santos PC, Gagliardi ACM, Miname MH, Chacra AP, Santos RD, Krieger JE, et al. SLCO1B1 haplotypes are not associated with atorvastatininduced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol. 2012; 68(3): 273-279.10.1007/s00228-011-1125-121928084Search in Google Scholar

20. Rodrigues AC, Perin PM, Purim SG, Silbiger VN, Genvigir FD, Willrich MA, et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci. 2011; 12(9): 5815-5827.10.3390/ijms12095815318975222016628Search in Google Scholar

21. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO 1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK 293 cells. Pharmacogenet Genomics. 2005; 15(7): 513-522.10.1097/01.fpc.0000170913.73780.5f15970799Search in Google Scholar

22. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic transporting polypep-tide-C (OATPC, SLCO1B1). Pharmacogenetics. 2004; 14(7): 429-440.10.1097/01.fpc.0000114750.08559.3215226675Search in Google Scholar

23. Couvert P, Giral P, Dejager S, Gu J, Huby T, Chapman MJ, et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics. 2008; 9(9): 1217-1227.10.2217/14622416.9.9.121718781850Search in Google Scholar

24. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005; 78(4): 330-341.10.1016/j.clpt.2005.06.01316198652Search in Google Scholar

25. Jada SR, Xiaochen S, Yan LY, Xiaoqiang X, Lal S, Zhou SF, et al. Pharmacogenetics of SLCO1B1: Haplotypes, htSNPs and hepatic expression in three distinct Asian populations. Eur J Clin Pharmacol. 2007; 63(6): 555-563.10.1007/s00228-007-0285-517415554Search in Google Scholar

26. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther. 2002; 302(2): 804-813.10.1124/jpet.302.2.80412130747Search in Google Scholar

27. Giannakopoulou E, Ragia G, Kolovou V, Tavridou A, Tselepis AD, Elisaf M, et al. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. Mol Biol Rep. 2014; 41(7): 4631-4638.10.1007/s11033-014-3334-z24668570Search in Google Scholar

28. Santos PC, Soares RA, Nascimento RM, Machado- Coelho GLL, Mill JG, Krieger JE, et al. SLCO1B1 rs414 9056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group. BMC Med Genet. 2011; 12(136): 1-6.Search in Google Scholar

29. Xu LY, He YJ, Zhang W, Deng S, Li Q, Zhang WX, et al. Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients. Acta Pharmacologica Sinica. 2007; 28(10): 1693-1697.10.1111/j.1745-7254.2007.00643.x17883959Search in Google Scholar

30. Daka A, Nestorovska AK, Radivojsa I, Mladenovska K, Vavlukis M, Dimovski A. Frequency of organic anion transporting polypeptide 1B1 SLCO1B1 gene variants in populations of patients treated with atorvastatin. Proceedings of the 41st European Society of Clinical Pharmacy Symposium on Clinical Pharmacy, October 29-31 2012, Barcelona, Spain.Search in Google Scholar

31. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005; 15(2): 97-98.10.1038/sj.cr.729027215740637Search in Google Scholar

32. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther. 2004; 75(5): 415-421.10.1016/j.clpt.2003.12.01615116054Search in Google Scholar

33. Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 2012; 12(3): 233-237.10.1038/tpj.2010.92Search in Google Scholar

34. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATPC (SLC 21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003; 73(6): 554-565.10.1016/S0009-9236(03)00060-2Search in Google Scholar

35. Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther. 2005; 78(4): 342-350.10.1016/j.clpt.2005.07.00316198653Search in Google Scholar

36. Mwinyi J, Kopke K, Schaefer M, Roots I, Gerloff T. Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur J Clin Pharmacol. 2008; 64(3): 257-266.10.1007/s00228-007-0409-y18185926Search in Google Scholar

37. Hubacek JA, Dlouha D, Adamkova V, Lanska V, Ceska R, Vrablik M. Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy. Neuro Endocrinol Lett. 2012; 33(Suppl 2): 22-25.Search in Google Scholar

38. Aklillu E, Mugusi S, Ngaimisi E, Hoffmann MM, Kцnig S, Ziesenitz V, et al. Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method. Eur J Clin Pharmacol. 2011; 67(11): 1139-1145.10.1007/s00228-011-1065-921630030Search in Google Scholar

39. Yang GP, Yuan H, Tang B, Zhang W, Wang LS, Huang ZJ, et al. Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients. Acta Pharmacologica Sinica. 2010; 31(3): 382-386.10.1038/aps.2009.203400240820140004Search in Google Scholar

40. Lin R, Wang X, Zhou W, Fu W, Wang Y, Huang W, et al. Association of polymorphisms in the solute carrier organic anion transporter family member 1B1 gene with essential hypertension in the Uyghur population. Ann Hum Genet. 2011; 75(2): 305-311. Search in Google Scholar